Cardiac cath lab technology developer Corindus Vascular Robotics has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of its CorPath robotic-assisted vascular intervention system in peripheral vascular interventions.
The new clearance was based on results of the Robotic-Assisted Peripheral Intervention for Peripheral Artery Disease (RAPID) clinical trial conducted at the Medical University of Graz in Austria, Corindus said. CorPath had previously received FDA clearances for percutaneous coronary interventions and radial percutaneous coronary interventions.
